ATF4 and hepatocellular carcinoma: In this study, we showed that PlGF inhibition reduced tumour hypoxia and PERK activation in vivo and that hypoxia activates the PERK/phospho-IF2α/ATF4 cascade in HCC cells, suggesting that tumour hypoxia mediates the observed PERK activation in HCC.